HiBob Named Best HR Management Software in the UK for 2026 
Ionik Announces 30-Day Extension of Senior Debt Facility 
NTG Clarity to Announce First Quarter Financial Results on May 27, 2026 with Earnings Call to Follow 
Voghion Expands Beyond Fashion to Build a One-Stop Lifestyle Platform Across Europe Vaxcyte to Present at Guggenheim 2nd Annual Vaccine and Infectious Disease Conference
FOSTER CITY, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation…
Terns Appoints Veteran Biopharmaceutical Executive Ann E. Taylor, M.D. to Board of Directors
FOSTER CITY, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the…
Satsuma Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA),…
Wave Life Sciences Announces New Data for Leading RNA Editing Capability Across Multiple Tissues and Provides Update on AATD Program During Analyst and Investor Research Webcast
Durable ADAR editing in vivo in preclinical models, including in CNS tissues with editing out…
Arcutis Expands Patent Portfolio with Roflumilast Pharmacokinetics Patent
WESTLAKE VILLAGE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage…
ERYTECH to Participate in the HealthTech Innovation Days (HTID) by France Biotech
ERYTECH to Participate in the HealthTech Innovation Days (HTID) by France Biotech Cambridge, MA (U.S.)…
FDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA for the Treatment of Factor VII Deficiency
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ: CBIO)…
Inventiva announces participation at several investor conferences in October 2021
Daix (France), Long Island City (New York, United States), September 28, 2021 – Inventiva (Euronext…
CORRECTION – Sorrento Therapeutics, Inc.
SAN DIEGO, Sept. 28, 2021 (GLOBE NEWSWIRE) — In a release issued on Tuesday, September 28th by Sorrento…
AB Science receives regulatory authorization to commence a second Phase 2 Covid-19 study
PRESS RELEASE AB SCIENCE RECEIVES REGULATORY AUTHORIZATION TO COMMENCE A SECOND PHASE 2 COVID STUDY…
Sorrento to Participate in the Benzinga Healthcare Small Cap Conference on September 30th
SAN DIEGO, Sept. 28, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) is…
Researchers Discover Previously Unknown Role of BioAegis’ Therapeutic Gelsolin as Key Signaling Protein Vital for Regulating Immune Cell Inflammatory Response
This biological phenomenon, quorum sensing in macrophages, regulates the transition of cells from inflammatory to…
Accelus Announces Event Schedule to Facilitate Peer-to-Peer Surgeon Education During the 36th Annual North American Spine Society Meeting in Boston
PALM BEACH GARDENS, Fla., Sept. 28, 2021 (GLOBE NEWSWIRE) — Accelus, a privately held medical…
LIDDS patent covering the NanoZolid® production process granted in Russia and Australia
UPPSALA, SWEDEN – LIDDS AB (publ) announces today that its most recent patent family on…
AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Studies of Ampligen as a Potential Early-Onset Therapeutic for COVID-19
AIM Has Reached Multiple Major Milestones Demonstrating Strong Progress in Developing its COVID-19 Portfolio OCALA,…
Scopus BioPharma’s Subsidiary Duet Therapeutics Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with…
Todos Medical Announces October Conference Calendar
New York, NY, and Tel Aviv, ISRAEL, Sept. 28, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Todos…
Marrone Bio Advances Novel Herbicides
Three Biological-Based Herbicides Enter Late-Stage Development Phases; Potential $27 Billion Market DAVIS, Calif., Sept. 28,…
Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx 99, an Experimental Prophylactic Treatment for the Prevention of Respiratory Viral Infections
– Phase 2b study will investigate the efficacy of REVTx-99 on viral load and patient-reported…
Fortress Biotech to Participate in the Benzinga Healthcare Small Cap Conference
NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an…